Rössler, Jochen <br/><br/>
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.  [electronic resource] 

 -  International journal of cancer  Jun 2011 
 - 2748-58 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.25611  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis<br/>Axitinib<br/>Blotting, Western<br/>Bone Marrow Neoplasms--drug therapy<br/>Child<br/>Drug Synergism<br/>Endothelium, Vascular--cytology<br/>Humans<br/>Imidazoles--therapeutic use<br/>Indazoles--therapeutic use<br/>Male<br/>Mice<br/>Mice, Nude<br/>Neovascularization, Pathologic--drug therapy<br/>Neuroblastoma--blood supply<br/>Phosphorylation<br/>Sirolimus--pharmacology<br/>Stem Cells--drug effects<br/>Tumor Cells, Cultured<br/>Vascular Endothelial Growth Factor Receptor-1--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-3--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays